Multiple cycles of high-dose doxorubicin and cyclophosphamide with G- CSF mobilized peripheral blood progenitor cell support in patients with metastatic breast cancer
Antineoplastic Combined Chemotherapy Protocols
Hematopoietic Stem Cell Mobilization
Hematopoietic Stem Cell Transplantation
The MTD of this three cycle high-dose regimen was doxorubicin 110 mg/m2 and cyclophosphamide 4 g/m2 with mucositis and cystitis being dose-limiting toxicities. Although the primary aim was not the evaluation of antitumour effect, this high-dose regimen does not appear to provide an improvement of treatment results in comparison with our previous study with the same drugs at moderately high-dosages without stem cell support.